000289652 001__ 289652
000289652 005__ 20250328112418.0
000289652 0247_ $$2doi$$a10.1186/s13008-024-00116-y
000289652 0247_ $$2pmid$$apmid:38643120
000289652 0247_ $$2pmc$$apmc:PMC11031927
000289652 0247_ $$2altmetric$$aaltmetric:162707387
000289652 037__ $$aDKFZ-2024-00834
000289652 041__ $$aEnglish
000289652 082__ $$a570
000289652 1001_ $$0P:(DE-He78)d06e5bb2d0828caa2be79a51825e84e1$$aPagliari, Francesca$$b0$$eFirst author$$udkfz
000289652 245__ $$aCancer radioresistance is characterized by a differential lipid droplet content along the cell cycle.
000289652 260__ $$aLondon$$bBioMed Central$$c2024
000289652 3367_ $$2DRIVER$$aarticle
000289652 3367_ $$2DataCite$$aOutput Types/Journal article
000289652 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1713773265_20489
000289652 3367_ $$2BibTeX$$aARTICLE
000289652 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289652 3367_ $$00$$2EndNote$$aJournal Article
000289652 500__ $$a#EA:E041#LA:E041#
000289652 520__ $$aCancer radiation treatments have seen substantial advancements, yet the biomolecular mechanisms underlying cancer cell radioresistance continue to elude full understanding. The effectiveness of radiation on cancer is hindered by various factors, such as oxygen concentrations within tumors, cells' ability to repair DNA damage and metabolic changes. Moreover, the initial and radiation-induced cell cycle profiles can significantly influence radiotherapy responses as radiation sensitivity fluctuates across different cell cycle stages. Given this evidence and our prior studies establishing a correlation between cancer radiation resistance and an increased number of cytoplasmic Lipid Droplets (LDs), we investigated if LD accumulation was modulated along the cell cycle and if this correlated with differential radioresistance in lung and bladder cell lines.Our findings identified the S phase as the most radioresistant cell cycle phase being characterized by an increase in LDs. Analysis of the expression of perilipin genes (a family of proteins involved in the LD structure and functions) throughout the cell cycle also uncovered a unique gene cell cycle pattern.In summary, although these results require further molecular studies about the mechanisms of radioresistance, the findings presented here are the first evidence that LD accumulation could participate in cancer cells' ability to better survive X-Ray radiation when cells are in the S phase. LDs can represent new players in the radioresistance processes associated with cancer metabolism. This could open new therapeutic avenues in which the use of LD-interfering drugs might enhance cancer sensitivity to radiation.
000289652 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000289652 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000289652 650_7 $$2Other$$aCancer metabolism
000289652 650_7 $$2Other$$aCell cycle
000289652 650_7 $$2Other$$aLipid droplets
000289652 650_7 $$2Other$$aPerilipins
000289652 650_7 $$2Other$$aRadioresistance
000289652 7001_ $$0P:(DE-He78)02e29e2d540ff21d777f3a03ec9f5ade$$aJansen, Jeannette$$b1$$eFirst author
000289652 7001_ $$0P:(DE-He78)483e25de20b0e09c44b46bdbdd7036c2$$aKnoll, Jan$$b2
000289652 7001_ $$0P:(DE-He78)15d0e694db442a1762a025b802a56f75$$aHanley, Rachel$$b3
000289652 7001_ $$0P:(DE-He78)102624aca75cfe987c05343d5fdcf2fe$$aSeco, Joao$$b4$$eLast author$$udkfz
000289652 7001_ $$0P:(DE-He78)62f71d68e658453766d3f349b2b718d4$$aTirinato, Luca$$b5$$eLast author
000289652 773__ $$0PERI:(DE-600)2236097-9$$a10.1186/s13008-024-00116-y$$gVol. 19, no. 1, p. 14$$n1$$p14$$tCell division$$v19$$x1747-1028$$y2024
000289652 8564_ $$uhttps://inrepo02.dkfz.de/record/289652/files/s13008-024-00116-y.pdf
000289652 8564_ $$uhttps://inrepo02.dkfz.de/record/289652/files/s13008-024-00116-y.pdf?subformat=pdfa$$xpdfa
000289652 8767_ $$8SN-2024-00560-b$$92024-02-20$$d2025-03-27$$eAPC$$jZahlung erfolgt
000289652 909CO $$ooai:inrepo02.dkfz.de:289652$$pVDB$$pOpenAPC$$popenCost
000289652 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d06e5bb2d0828caa2be79a51825e84e1$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000289652 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)02e29e2d540ff21d777f3a03ec9f5ade$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000289652 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)483e25de20b0e09c44b46bdbdd7036c2$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000289652 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)15d0e694db442a1762a025b802a56f75$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000289652 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)102624aca75cfe987c05343d5fdcf2fe$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000289652 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)62f71d68e658453766d3f349b2b718d4$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000289652 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000289652 9141_ $$y2024
000289652 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELL DIV : 2022$$d2023-08-19
000289652 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-19
000289652 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-19
000289652 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-19
000289652 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T09:07:18Z
000289652 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T09:07:18Z
000289652 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-05-02T09:07:18Z
000289652 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-19
000289652 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-19
000289652 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-19
000289652 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-19
000289652 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-19
000289652 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-19
000289652 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-19
000289652 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-19
000289652 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-19
000289652 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-19
000289652 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-19
000289652 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000289652 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000289652 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
000289652 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
000289652 9202_ $$0I:(DE-He78)E041-20160331$$kE041$$lMed. Physik in der Radioonkologie$$x0
000289652 9201_ $$0I:(DE-He78)E041-20160331$$kE041$$lMed. Physik in der Radioonkologie$$x0
000289652 9200_ $$0I:(DE-He78)E041-20160331$$kE041$$lMed. Physik in der Radioonkologie$$x0
000289652 980__ $$ajournal
000289652 980__ $$aVDB
000289652 980__ $$aI:(DE-He78)E041-20160331
000289652 980__ $$aUNRESTRICTED
000289652 980__ $$aAPC